Differences in Botulinum Toxin Dosing Between Patients With Adductor Spasmodic Dysphonia and Essential Voice Tremor

被引:11
作者
Orbelo, Diana M. [1 ,2 ]
Duffy, Joseph R. [2 ]
Borst, Becky J. Hughes [1 ]
Ekbom, Dale [1 ]
Maragos, Nicolas E. [1 ]
机构
[1] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55901 USA
[2] Mayo Clin, Dept Neurol, Div Speech Pathol, Rochester, MN 55901 USA
关键词
Spasmodic dysphonia; Botulinum toxin; Tremor; Dystonia; Dystonic tremor; Essential voice tremor; SPASTIC DYSPHONIA; VOCAL TREMOR; LARYNGEAL DYSTONIA; RISK-FACTORS; EXPERIENCE; MANAGEMENT;
D O I
10.1016/j.jvoice.2013.05.008
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Objectives. To explore possible dose differences in average botulinum toxin (BTX) given to patients with adductor spasmodic dysphonia (ADSD) compared with patients with essential voice tremor (EVT). Methods. A retrospective study compared the average BTX dose injected in equal doses to the thyroarytenoid (TA) muscles of 51 patients with ADSD with 52 patients with EVT. Results. Those with ADSD received significantly higher total doses (6.80 +/- 2.79 units) compared with those with EVT (5.02 +/- 1.65 units). Dose at time of first injection, age at time of first injection, gender, year of first injection, and average time between injections were included in multivariate analysis but did not interact with total average dose findings. Conclusions. Patients with ADSD may need relatively higher doses of BTX injections to bilateral TA muscles compared with patients with EVT.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 33 条
[1]   Botulinum toxin type A for treating voice tremor [J].
Adler, CH ;
Bansberg, SF ;
Hentz, JG ;
Ramig, LO ;
Buder, EH ;
Witt, K ;
Edwards, BW ;
Krein-Jones, K ;
Caviness, JN .
ARCHIVES OF NEUROLOGY, 2004, 61 (09) :1416-1420
[2]  
[Anonymous], 2009, CLIN VOICE DISORDERS
[3]   ADDUCTOR SPASTIC DYSPHONIA AS A SIGN OF ESSENTIAL (VOICE) TREMOR [J].
ARONSON, AE ;
HARTMAN, DE .
JOURNAL OF SPEECH AND HEARING DISORDERS, 1981, 46 (01) :52-58
[4]   SPASTIC DYSPHONIA .2. COMPARISON WITH ESSENTIAL (VOICE) TREMOR AND OTHER NEUROLOGIC AND PSYCHOGENIC DYSPHONIAS [J].
ARONSON, AE ;
BROWN, JR ;
LITIN, EM ;
PEARSON, JS .
JOURNAL OF SPEECH AND HEARING DISORDERS, 1968, 33 (03) :219-231
[5]   Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges [J].
Barkmeier, JM ;
Case, JL ;
Ludlow, CL .
JOURNAL OF COMMUNICATION DISORDERS, 2001, 34 (1-2) :21-37
[6]   Botulinum toxin management of spasmodic dysphonia (Laryngeal dystonia): A 12-year experience in more than 900 patients [J].
Blitzer, A ;
Brin, MF ;
Stewart, CF .
LARYNGOSCOPE, 1998, 108 (10) :1435-1441
[7]   Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series [J].
Blitzer, A. .
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 :28-30
[8]  
BLITZER A, 1988, LARYNGOSCOPE, V98, P636
[9]   Botulinum toxin: Basic science and clinical uses in otolaryngology [J].
Blitzer, A ;
Sulica, L .
LARYNGOSCOPE, 2001, 111 (02) :218-226
[10]   Development and validation of the vocal tremor scoring system [J].
Bove, Michiel ;
Daamen, Nicole ;
Rosen, Clark ;
Wang, Chen-Chi ;
Sulica, Lucian ;
Gartner-Schmidt, Jackie .
LARYNGOSCOPE, 2006, 116 (09) :1662-1667